Moelis & Co has a consensus price target of $50.69 based on the ratings of 14 analysts. The high is $68 issued by Morgan Stanley on October 11, 2021. The low is $36 issued by Morgan Stanley on July 18, 2022. The 3 most-recent analyst ratings were released by JP Morgan, Keefe, Bruyette & Woods, and Morgan Stanley on July 25, 2024, July 25, 2024, and July 23, 2024, respectively. With an average price target of $57.33 between JP Morgan, Keefe, Bruyette & Woods, and Morgan Stanley, there's an implied -15.79% downside for Moelis & Co from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/25/2024 | Buy Now | -25.09% | JP Morgan | Kenneth Worthington | $50 → $51 | Maintains | Neutral | Get Alert |
07/25/2024 | Buy Now | -11.87% | Keefe, Bruyette & Woods | Aidan Hall | $54 → $60 | Reiterates | Market Perform → Market Perform | Get Alert |
07/23/2024 | Buy Now | -10.4% | Morgan Stanley | Ryan Kenny | $51 → $61 | Maintains | Underweight | Get Alert |
07/11/2024 | Buy Now | -26.56% | JP Morgan | Kenneth Worthington | $54 → $50 | Maintains | Neutral | Get Alert |
07/09/2024 | Buy Now | -26.56% | UBS | Brennan Hawken | $47 → $50 | Maintains | Sell | Get Alert |
04/25/2024 | Buy Now | -30.96% | UBS | Brennan Hawken | $45 → $47 | Maintains | Sell | Get Alert |
04/25/2024 | Buy Now | -20.68% | Keefe, Bruyette & Woods | Aidan Hall | $58 → $54 | Reiterates | Market Perform → Market Perform | Get Alert |
04/09/2024 | Buy Now | — | JMP Securities | Devin Ryan | — | Reiterates | → Market Perform | Get Alert |
03/26/2024 | Buy Now | -33.9% | UBS | Brennan Hawken | $46 → $45 | Maintains | Sell | Get Alert |
03/13/2024 | Buy Now | -14.81% | Goldman Sachs | James Yaro | $53 → $58 | Upgrade | Sell → Neutral | Get Alert |
02/08/2024 | Buy Now | -16.27% | JP Morgan | Kenneth Worthington | $46 → $57 | Maintains | Neutral | Get Alert |
01/29/2024 | Buy Now | -17.74% | Keefe, Bruyette & Woods | Michael Brown | → $56 | Reinstates | → Market Perform | Get Alert |
12/19/2023 | Buy Now | -30.96% | Goldman Sachs | James Yaro | $41 → $47 | Maintains | Sell | Get Alert |
11/03/2023 | Buy Now | -44.18% | Morgan Stanley | Ryan Kenny | $39 → $38 | Maintains | Underweight | Get Alert |
10/03/2023 | Buy Now | -55.93% | UBS | Brennan Hawken | $29 → $30 | Maintains | Sell | Get Alert |
07/27/2023 | Buy Now | -17.74% | JP Morgan | Kenneth Worthington | $45 → $56 | Maintains | Neutral | Get Alert |
07/12/2023 | Buy Now | -42.71% | Morgan Stanley | Ryan Kenny | $29 → $39 | Maintains | Underweight | Get Alert |
07/12/2023 | Buy Now | -41.25% | Goldman Sachs | James Yaro | $35 → $40 | Maintains | Sell | Get Alert |
06/27/2023 | Buy Now | -57.4% | Morgan Stanley | Ryan Kenny | $29 → $29 | Reiterates | Underweight → Underweight | Get Alert |
04/27/2023 | Buy Now | -45.65% | Keefe, Bruyette & Woods | Matthew Moon | $40 → $37 | Maintains | Underperform | Get Alert |
04/12/2023 | Buy Now | -57.4% | Morgan Stanley | Ryan Kenny | $30 → $29 | Maintains | Underweight | Get Alert |
03/24/2023 | Buy Now | -47.12% | Goldman Sachs | James Yaro | $40 → $36 | Maintains | Sell | Get Alert |
02/09/2023 | Buy Now | -38.31% | Goldman Sachs | Richard Ramsden | $38 → $42 | Maintains | Sell | Get Alert |
01/11/2023 | Buy Now | -45.65% | Goldman Sachs | James Yaro | $40 → $37 | Downgrade | Neutral → Sell | Get Alert |
01/09/2023 | Buy Now | -55.93% | UBS | Brennan Hawken | $32 → $30 | Maintains | Sell | Get Alert |
11/03/2022 | Buy Now | -41.25% | JP Morgan | Kenneth Worthington | $42 → $40 | Maintains | Neutral | Get Alert |
11/03/2022 | Buy Now | -45.65% | Keefe, Bruyette & Woods | Michael Brown | $40 → $37 | Downgrade | Market Perform → Underperform | Get Alert |
10/07/2022 | Buy Now | -44.18% | Goldman Sachs | Richard Ramsden | $43 → $38 | Maintains | Neutral | Get Alert |
09/23/2022 | Buy Now | -48.59% | UBS | Brennan Hawken | $43 → $35 | Downgrade | Neutral → Sell | Get Alert |
07/28/2022 | Buy Now | -36.84% | UBS | Brennan Hawken | $40 → $43 | Maintains | Neutral | Get Alert |
07/18/2022 | Buy Now | -47.12% | Morgan Stanley | Manan Gosalia | $53 → $36 | Downgrade | Equal-Weight → Underweight | Get Alert |
07/11/2022 | Buy Now | -38.31% | Wolfe Research | Steven Chubak | → $42 | Downgrade | Peer Perform → Underperform | Get Alert |
07/08/2022 | Buy Now | -33.9% | Piper Sandler | Jeffery Harte | $50 → $45 | Maintains | Neutral | Get Alert |
07/06/2022 | Buy Now | -41.25% | UBS | Brennan Hawken | $54 → $40 | Downgrade | Buy → Neutral | Get Alert |
04/28/2022 | Buy Now | -26.56% | Piper Sandler | Jeffery Harte | → $50 | Downgrade | Overweight → Neutral | Get Alert |
04/12/2022 | Buy Now | -33.9% | Goldman Sachs | Richard Ramsden | $50 → $45 | Maintains | Neutral | Get Alert |
04/07/2022 | Buy Now | -23.62% | Piper Sandler | Jeffery Harte | $61 → $52 | Maintains | Overweight | Get Alert |
04/06/2022 | Buy Now | -16.27% | Keefe, Bruyette & Woods | Michael Brown | → $57 | Downgrade | Outperform → Market Perform | Get Alert |
03/09/2022 | Buy Now | -10.4% | Piper Sandler | Jeffery Harte | $70 → $61 | Maintains | Overweight | Get Alert |
03/08/2022 | Buy Now | -22.15% | Morgan Stanley | Mana Gosalia | $65 → $53 | Maintains | Equal-Weight | Get Alert |
02/11/2022 | Buy Now | 2.82% | Piper Sandler | Jeffery Harte | $78 → $70 | Upgrade | Neutral → Overweight | Get Alert |
02/10/2022 | Buy Now | -4.52% | Morgan Stanley | Mana Gosalia | $68 → $65 | Maintains | Equal-Weight | Get Alert |
01/06/2022 | Buy Now | -4.52% | Goldman Sachs | Richard Ramsden | $68 → $65 | Upgrade | Sell → Neutral | Get Alert |
01/04/2022 | Buy Now | 7.23% | UBS | Brennan Hawken | $85 → $73 | Maintains | Buy | Get Alert |
12/17/2021 | Buy Now | 13.1% | Keefe, Bruyette & Woods | Michael Brown | — | Upgrade | Market Perform → Outperform | Get Alert |
12/08/2021 | Buy Now | -0.12% | Morgan Stanley | Mana Gosalia | — | Maintains | Equal-Weight | Get Alert |
10/11/2021 | Buy Now | -0.12% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
The latest price target for Moelis (NYSE:MC) was reported by JP Morgan on July 25, 2024. The analyst firm set a price target for $51.00 expecting MC to fall to within 12 months (a possible -25.09% downside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Moelis (NYSE:MC) was provided by JP Morgan, and Moelis maintained their neutral rating.
The last upgrade for Moelis & Co happened on March 13, 2024 when Goldman Sachs raised their price target to $58. Goldman Sachs previously had a sell for Moelis & Co.
The last downgrade for Moelis & Co happened on January 11, 2023 when Goldman Sachs changed their price target from $40 to $37 for Moelis & Co.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moelis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moelis was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
While ratings are subjective and will change, the latest Moelis (MC) rating was a maintained with a price target of $50.00 to $51.00. The current price Moelis (MC) is trading at is $68.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.